1. A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy 
William C. Jackson, MD, Felix Y. Feng, MD, Stephanie Daignault, PhD, Maha Hussain, MD, David Smith, MD, Kathleen Cooney, MD, Kenneth Pienta, MD, Shruti Jolly, MD, Brent Hollenbeck, MD, Karin B. Olson, PA-C, Howard M. Sandler, MD, Michael E. Ray, MD, PhD, Daniel A. Hamstra, MD, PhD 
Advances in Radiation Oncology 
Volume 1, Issue 1, Pages (January 2016)
DOI: /j.adro
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

2. Figure 1
(A) Freedom from grade 2+ late urinary toxicity (P = .41) and (B) late rectal toxicity (P = .60). Freedom from (C) biochemical progression (HR, 098 [90% CI, ], P = .9648) and (D) from metastasis (HR 0.29 [90% CI, ], P = CI, confidence interval; HR, hazard ratio; SRT, salvage radiation therapy.
Advances in Radiation Oncology 2016 1, 59-66DOI: ( /j.adro )
Copyright © 2016 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions